INmune Bio (NASDAQ:INMB) posted its quarterly earnings data on Friday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.09), Fidelity Earnings reports.

Shares of NASDAQ INMB opened at $4.52 on Friday. The firm has a 50-day simple moving average of $4.94 and a 200-day simple moving average of $7.92. The company has a current ratio of 20.94, a quick ratio of 20.94 and a debt-to-equity ratio of 0.01. INmune Bio has a 52 week low of $3.51 and a 52 week high of $11.50.

In other INmune Bio news, Director Scott Juda acquired 5,000 shares of the stock in a transaction dated Wednesday, August 21st. The stock was acquired at an average price of $6.00 per share, with a total value of $30,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders bought 12,918 shares of company stock valued at $77,109. Insiders own 67.67% of the company’s stock.

Several equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $11.50 price objective on shares of INmune Bio in a report on Thursday, September 12th. Maxim Group set a $13.00 target price on shares of INmune Bio and gave the company a “buy” rating in a research report on Friday, September 13th.

INmune Bio Company Profile

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Featured Article: 52 Week Highs

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with's FREE daily email newsletter.